%0 Journal Article
%A Fortner, Renée T
%A Sarink, Danja
%A Schock, Helena
%A Johnson, Theron
%A Tjønneland, Anne
%A Olsen, Anja
%A Overvad, Kim
%A Affret, Aurélie
%A His, Mathilde
%A Boutron-Ruault, Marie-Christine
%A Boeing, Heiner
%A Trichopoulou, Antonia
%A Naska, Androniki
%A Orfanos, Philippos
%A Palli, Domenico
%A Sieri, Sabina
%A Mattiello, Amalia
%A Tumino, Rosario
%A Ricceri, Fulvio
%A Bueno-de-Mesquita, H Bas
%A Peeters, Petra H M
%A Van Gils, Carla H
%A Weiderpass, Elisabete
%A Lund, Eiliv
%A Quirós, J Ramón
%A Agudo, Antonio
%A Sanchez-Perez, Maria-Jose
%A Chirlaque, María-Dolores
%A Ardanaz, Eva
%A Dorronsoro, Miren
%A Key, Tim
%A Khaw, Kay-Tee
%A Rinaldi, Sabina
%A Dossus, Laure
%A Gunter, Marc
%A Merritt, Melissa A
%A Riboli, Elio
%A Kaaks, Rudolf
%T Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort
%D 2017
%U http://hdl.handle.net/10668/2647
%X BACKGROUND:Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.METHODS:A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.RESULTS:The associations between OPG and ER+ and ER- breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER- breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p trend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER- disease did not differ by menopausal status at blood collection (p het = 0.97), and we observed no heterogeneity by HT use at blood collection (p het ≥ 0.43) or age at breast cancer diagnosis (p het ≥ 0.30).CONCLUSIONS:This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER- breast cancer.
%K Breast cancer
%K Neoplasias de la mama
%K Estrogen receptor
%K Hormone receptor
%K Osteoprotegerin
%K Osteoprotegerina
%K Progesterone receptor
%K Receptores de progesterona
%K Receptores estrogénicos
%K Receptores de hormonas
%K RANK axis
%~